HIV

Global Meningitis Imaging Market Forecast Report to 2027 - Market Growth of 4.3% CAGR During 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 13, 2022
Infectious Diseases, Health, Other Health, People, COVID-19, Knowledge, Tuberculosis, Infection, World, CT, Viral meningitis, Magnetic resonance imaging, Patient, World Health Organization, MRI, Fungal meningitis, WHO, Meningitis, Inflammation, Immune system, HIV, CAGR, Prevalence, Growth, Medical device, Medical imaging

The "Global Meningitis Imaging Market By Product Type, By Disease Type, By End User, By Regional Outlook, Industry Analysis Report and Forecast, 2021-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Meningitis Imaging Market By Product Type, By Disease Type, By End User, By Regional Outlook, Industry Analysis Report and Forecast, 2021-2027" report has been added to ResearchAndMarkets.com's offering.
  • The Global Meningitis Imaging Market size is expected to reach $223.7 thousands by 2027, rising at a market growth of 4.3% CAGR during the forecast period.
  • The COVID-19 outbreak is expected to have a positive impact on the worldwide meningitis imaging market.
  • North America dominated the meningitis imaging market in 2020 and is expected to continue to do so during the forecast period.

MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test

Retrieved on: 
Thursday, May 12, 2022
Severe acute respiratory syndrome coronavirus 2, Risk, Company, Infection, NTP, News, TSX Venture Exchange, EU, Antibody, CE, European, COVID-19, TSX, Global health, FDA, Syphilis, Awareness, Pharmacy, Hospital, MIR, Union, Biomarker, VDRL, RPR, Hepatitis, LinkedIn, CDC, Twitter, HIV, RVF, Collection, Growth, Diagnosis, CEO, Achievement, GLOBE, Pharmaceutical industry

HALIFAX, Nova Scotia, May 12, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the achievement of another milestone in its regulatory strategy by receiving the CE mark for its Multiplo Complete Syphilis (TP/nTP) Antibody Test (Multiplo TP/nTP).

Key Points: 
  • HALIFAX, Nova Scotia, May 12, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the achievement of another milestone in its regulatory strategy by receiving the CE mark for its Multiplo Complete Syphilis (TP/nTP) Antibody Test (Multiplo TP/nTP).
  • This approval allows the Company to further strengthen its product offering in all markets accepting the CE mark.
  • MedMira received the CE mark in March 2022 for its Reveal TP (Syphilis) Antibody Test (Reveal TP) aimed at diagnosing potential acute syphilis infections.
  • MedMiras Multiplo TP/nTP, on the other hand, will provide a complete system which combines both screening and confirmation in one test.

Indaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 12, 2022
Therapeutic index, Risk, Company, Cancer, Immunotherapy, Neoplasm, Private Securities Litigation Reform Act, Research, TLR, Infection, HBV, GMP, U.S. Securities and Exchange Commission, Nasdaq, Government, Therapy, NHL, Clinical trial, Immunology, FDA, IND, NSAID, Toxicity, Forward-looking statement, Hepatocellular carcinoma, Technology, Gram-negative bacteria, Immune system, HIV, SEC, Security (finance), Investigational New Drug, Annual report, GLOBE, Online gambling, Pharmaceutical industry, Vaccine, Cryptocurrency

NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announces financial results for the first quarter ended March 31, 2022 and provides a corporate update.

Key Points: 
  • NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company), today announces financial results for the first quarter ended March 31, 2022 and provides a corporate update.
  • This is a significant milestone for Indaptus as it advances our approach to induce multiple immune system components as a mechanism to combat solid tumors.
  • Today, Indaptus announces the submission of its Investigational New Drug Application (IND) for Decoy20.
  • The Company continues to expect to initiate a Phase 1 clinical trial for Decoy20 targeting solid tumorsin 2022.

Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases

Retrieved on: 
Thursday, May 12, 2022
Research, Seniors, Dental, Clinical Trials, Biotechnology, Health, Consumer, Pharmaceutical, Science, Dignity, Inflammation, Degenerative disease, Dignity Health St. Joseph's Hospital and Medical Center, Hospital, MA, International Conference on Emerging Infectious Diseases, GAIN, Journal, Nasdaq, Harvard School of Dental Medicine, 2021 Essex County Council election, Patient, Analytics, Barrow Neurological Institute, Editing, Porphyromonas gingivalis, University of California, San Francisco, NIH, Research, Brain, Dentistry, Postgraduate education, Conference, Neurodegeneration, Editorial board, Human, University, Pathology, Twitter, HIV, Medical Center, Laboratory, Pharmaceutical industry, Corporation, Periodontology

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, announced that the company will participate at The 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases (PgLouisville2022) taking place May 15-17, 2022 in Louisville, Kentucky.

Key Points: 
  • Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, announced that the company will participate at The 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases (PgLouisville2022) taking place May 15-17, 2022 in Louisville, Kentucky.
  • Cortexymes clinical advisory board member Mark Ryder, D.M.D., will provide an overview of GAIN Trial results and biomarker data examining the role of P. gingivalis in oral and systemic diseases.
  • He serves as an Associate Editor of the Journal of Periodontal Research and is on the Editorial Board of several dental research journals.
  • Access: Cortexymes PgLouisville2022 presentation will be accessible on the Science section of the companys website at www.cortexyme.com on May 16, 2022.

BD Launches Fully Automated, High-Throughput Infectious Disease Molecular Diagnostic Platform in the U.S.

Retrieved on: 
Thursday, May 12, 2022
Risk, DNA, STI, Disease, Company, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Urine, CT, BD, Patient, Solution, Health, Trichomonas, CE, COVID-19, Collection, Becton, FDA, Efficiency, GC, Female, Trichomonas vaginalis, Pregnancy, Neisseria gonorrhoeae, Safety, Organization, MX, BDX, Human papillomavirus infection, Therapy, LinkedIn, Twitter, HIV, Becton, Dickinson and Company headquarters, GX, Male, Laboratory, NYSE, Chlamydia trachomatis, HPV, Pharmaceutical industry, Medical device, Chlamydia

FRANKLIN LAKES, N.J., May 12, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. launch of its new, fully automated, high-throughput infectious disease molecular diagnostics platform.

Key Points: 
  • FRANKLIN LAKES, N.J., May 12, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. launch of its new, fully automated, high-throughput infectious disease molecular diagnostics platform.
  • With 510(k) clearance from the U.S. Food and Drug Administration (FDA), the new BD COR MX instrument is a new analytic instrument option for the BD COR System.
  • The BD COR MX/PX System integrates and automates the complete molecular laboratory workflow, from sample processing to diagnostic test result for large, high-throughput labs.
  • The BD COR System is fully automated, modular, and scalable instrument, designed to address multiple needs within laboratories to handle expanding molecular testing volumes.

Caribou Biosciences Announces Appointment of David Johnson to its Board of Directors

Retrieved on: 
Wednesday, May 11, 2022
Phenotype, UNC Kenan–Flagler Business School, Risk, DNA, Genome, Private Securities Litigation Reform Act, CRISPR/Cpf1, U.S. Securities and Exchange Commission, Nasdaq, Rachel Haurwitz, Puget Sound, Patient, Therapy, Clinical trial, Gilead Sciences, Lymphatic system, Marketing, Research, Efficiency, IND, CRISPR, RNA, University, Safety, GlaxoSmithKline, HIV, Security (finance), University of North Carolina School of Law, Annual report, GLOBE, Pharmaceutical industry, Reindeer

BERKELEY, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of David L. Johnson to its board of directors.

Key Points: 
  • BERKELEY, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of David L. Johnson to its board of directors.
  • I look forward to working with the Caribou leadership team and other board members as the company develops and advances its pipeline.
  • Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases.
  • Caribou Biosciences and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

Global Medical Gloves Market Trajectory & Analytics Report 2022-2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 11, 2022
Medical Supplies, Health, COVID-19, Diabetic foot ulcer, Hygiene, Population, Dengue fever, Safety, Prevalence, Golden Gloves, Infection, STD, HIV, Cancer, Diagnosis, Incidence, Hospital, Medical tourism, Conditional sentence, Adoption, Subclinical infection, CAGR, Technology, SARS, Growth, Awareness, Risk, AIDS, Personal protective equipment, Pet, Medical device

The "Medical Gloves - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Gloves - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • This segment currently accounts for a 20.7% share of the global Medical Gloves market.
  • Europe is projected to remain the second leading market in the global medical gloves market due to increasing healthcare spending and extensive adoption of disposable medical gloves while performing surgical procedures.
  • The regional market for medical gloves is likely to be also propelled by increasing medical tourism, adoption of sophisticated products and rising healthcare awareness across rural areas.

Panel to talk about social justice for a more empathetic world

Retrieved on: 
Wednesday, May 11, 2022
Innovation, Social justice, Association of North American Graduate Programs in the Conservation of Cultural Property, Canada Foundation for Innovation, University, YouTube, Twitter, Ontario Institute for Studies in Education, GLOBE, Canada Research Chair, Empowerment, Environmental health, Reproductive health, Human, Humanities, Graduate school, CFI, HIV, Climate change, Faculty (division), Social, Woman, Knowledge, Institute, FHSS, Thompson Rivers University, Facebook, Social science, Faculty, Publication, Health, Quality of life, University of Auckland Faculty of Education and Social Work, LinkedIn, Social work, Congress, Public health, Federation, Master, Research, SRH, Marketing, Toy, Medicine, Education

OTTAWA, May 11, 2022 (GLOBE NEWSWIRE) -- Young adults are navigating a rapidly changing world where climate change, social justice, and the economic and societal aftermath of the pandemic will be the defining events of their youth. But with change comes an extraordinary opportunity for this generation to embrace a more empathetic value system and define their own futures.

Key Points: 
  • The panel hopes to engage young people in answering the question, What does social justice mean for you today, and how can research help advance it to forge the future you want?
  • Four experts will address this question by sharing their research in fields ranging from climate activism, social justice learning, queer and gender difference, and health and well-being.
  • Lesley Gittings is a postdoctoral research fellow with an interest in social justice, and the social and structural factors that shape health across the life course.
  • From 2002-07 he held the Canada Research Chair of Social Justice and Cultural Studies at Ontario Institute for Studies in Education.

Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab) for Immune Restoration/Functional Cure of HIV-1 Infected Patients

Retrieved on: 
Wednesday, May 11, 2022
Investigational New Drug, COVID-19, No, Acne, IND, Degenerative disease, ART, Pharmacokinetics, Cart, Food and Drug Administration, Food, Viremia, Safety, CDC, Prevalence, HBV, Patient, Doctor of Philosophy, HIV-1, Infection, HIV, FDA, FACT, CHB, Incidence, PBC, Hepatitis B, UNAIDS, Death, HIV/AIDS, HKEX, Hong Kong Stock Exchange, NASH, PD-L1, Fatty liver disease, Primary biliary cholangitis, CEO, U.S. FDA, AIDS, Pharmaceutical industry, Vaccine

HANGZHOU, China and SHAOXING, China, May 10, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today the Investigational New Drug (IND) application approval of ASC22 (Envafolimab) by U.S. Food and Drug Administration (FDA) for the indication of immune restoration/functional cure of human immunodeficiency virus 1 (HIV-1) infected patients.

Key Points: 
  • HANGZHOU, China and SHAOXING, China, May 10, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today the Investigational New Drug (IND) application approval of ASC22 (Envafolimab) by U.S. Food and Drug Administration (FDA) for the indication of immune restoration/functional cure of human immunodeficiency virus 1 (HIV-1) infected patients.
  • ASC22 (Envafolimab) is a subcutaneously administered single domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection.
  • Immune restoration/functional cure in HIV-1 infected patients is the second indication of ASC22 that obtained IND approval from U.S. FDA, in addition to the indication of functional cure of chronic hepatitis B (CHB) patients.
  • "U.S. IND approval of ASC22 (Envafolimab) for HIV/AIDS treatment is a major step in our effort to pursue HIV functional cure.

Appointments in Conjunction With Theratechnologies Annual Meeting

Retrieved on: 
Tuesday, May 10, 2022
Board, COVID-19, Forward-looking statement, Investment, NASDAQ, Company, Public expenditure, Judgement, HIV, FDA, Human, Cancer, Chairperson, Marketing, Sale, EDGAR, TSX, CEO, Research, Awareness, SEDAR, Management, Pharmaceutical industry

To have the best shot at delivering the healthiest return on investment for shareholders, you need to have both.

Key Points: 
  • To have the best shot at delivering the healthiest return on investment for shareholders, you need to have both.
  • Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs.
  • Further information about Theratechnologies is available on the Company's website at www.theratech.com , on SEDAR at www.sedar.com and on EDGAR at www.sec.gov .
  • The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements.